“As part of our company growth planning, I commissioned Milner to create and run a special strategy workshop for my board and management team in Paris. Before the workshop, Nick Milner interviewed all the attendees to understand their view on the opportunities and the threats. He also arranged for specific attendees to prepare presentations on key topics to present at the workshop. The two-day workshop agenda included presentations, syndicate exercises and discussion sessions. The day after the workshop, I received a copy of a draft strategy document and a copy of all the slides and material created at the workshop. The whole process was expertly run and my colleagues thought it was a great success. Following the workshop, I personally appreciated the practical input and recommendations about what needs to be done to deliver our strategy from sales, to our web and PR plans. I highly recommend the Milner strategy workshop.”
Mohammad Afshar, MD, PhD
CEO Ariana Pharma
Ariana wanted to make sure it was focussing its commercial and economic resources in the right areas. To support this objective, Milner Strategic Marketing designed and ran a 2-day workshop and produced a draft corporate strategy document.
As a result of Ariana Pharma’s strategy review, resources were reprioritised and the company has had its most successful commercial year since its foundation in 2003. Click here to see the full case study
Ariana Pharma is a premium provider of advanced, clinical and biomarker data analytics technology. Ariana’s unique technology exhaustively mines data, increasing the success of both clinical trials and multi-parametric diagnostic tools. Our team of biostatisticians, software developers, clinical experts and business developers works hard to save sponsors both time and money.
Ariana analyzes multi-parametric data (biochemical, genomic, proteomic, genetic, metabolic, patient characteristics, etc.) to identify patient responders and reduce clinical and drug development risk. Our technology also optimizes clinical trial inclusion/exclusion criteria, and identifies patients at risk of adverse events, thus reducing recruitment costs while detecting hidden signals and working with incomplete data sets. Overall, we have a flawless track record of maximizing the value of clinical assets.
Our methodology is implemented via our innovative software platform KEM® (Knowledge Extraction and Management), a system uniquely conceived and developed here at Ariana Pharma, with strong collaboration with academic (The Pasteur Institute, CNRS) and industry groups (GSK, Novartis, Pfizer, etc.). KEM® is an effective technology used across the life science industry, including organizations such as the FDA, that can accelerate the discovery and development process.< Back